Sumitomo Pharma America, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Phase 1 Study of Oral TP-1454
- Conditions
- Interventions
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04328740
- Locations
- ๐บ๐ธ
Texas Oncology Baylor Sammons Cancer Center, Dallas, Texas, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธMayo Clinic Jacksonville, Jacksonville, Florida, United States
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04299880
- Locations
- ๐ฏ๐ต
Kyorin University Hospital, Tokyo, Japan
๐บ๐ธMaine Center for Cancer Medicine, Scarborough, Maine, United States
๐บ๐ธWinship Cancer Institute, Emory University, Atlanta, Georgia, United States
A Study of Oral TP-3654 in Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04176198
- Locations
- ๐บ๐ธ
University of Maryland, Baltimore, Maryland, United States
๐บ๐ธUniversity of Minnesota, Minneapolis, Minnesota, United States
๐บ๐ธMontefiore Cancer Center, Bronx, New York, United States
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04038957
- Locations
- ๐ฌ๐ง
King's College London, London, United Kingdom
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03969420
- Locations
- ๐บ๐ธ
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธOrlando Health, Inc, Univ of Florida Health Cancer Center, Orlando, Florida, United States
Study of TP-3654 in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03715504
- Locations
- ๐บ๐ธ
Huntsman Cancer Institute, Salt Lake City, Utah, United States
๐บ๐ธMD Anderson, Houston, Texas, United States
๐บ๐ธUniversity of Virginia, Charlottesville, Virginia, United States
A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03627195
- Locations
- ๐บ๐ธ
Dr. David Walling, Long Beach, California, United States
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03604783
- Locations
- ๐บ๐ธ
US Oncology - Texas Oncology - Tyler, Tyler, Texas, United States
๐บ๐ธMemorial Sloan Kettering, New York, New York, United States
๐บ๐ธUS Oncology - Greenville Health System, Greenville, South Carolina, United States
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03593915
- Locations
- ๐บ๐ธ
University of Iowa, Iowa City, Iowa, United States
๐บ๐ธColumbia University, New York, New York, United States
๐บ๐ธUS Oncology - Texas Oncology - Austin Midtown, Austin, Texas, United States
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03572634
- Locations
- ๐บ๐ธ
Mayo Clinic Florida, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic Arizona, Phoenix, Arizona, United States
๐บ๐ธDuke University, Durham, North Carolina, United States